Nectin Therapeutics Announces Extended Series A Financing to Over $25M and Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors
Summary
First-in-Human Phase 1 Clinical Trial in Advanced Solid Tumors is Being Conducted by MD Anderson with an Investment from Cancer Focus Fund Extension Brings in New Investor Israel Biotech Fund (IBF), with Additional Participation from Existing Investors JERUSALEM and FORT LEE, NJ, Nov. 30, 2022 /PRNewswire/ -- ., (Nectin) a biotechnology company developing novel targeted immunotherapies to address resistance to approved immuno-oncology (IO) treatments, announced today dosing of the first patient in its Phase 1 clinical trial of NTX1088, Nectins first-in-class PVR (CD155) blocker, in cancer patients with locally advanced and metastatic solid tumors. PVR blockade additionally stimulates an anti-tumor immune response by preventing the immune-suppressing signaling of the two checkpoint receptors TIGIT and CD96.PVR is overexpressed in many solid tumors across different cancer indications, including lung, colorectal, liver, ovarian, breast, adrenal, pancreatic, uterine, head and neck, gastric and esophageal. "PVR blockade by NTX1088, with its first-in-class differentiated mechanism of action, has demonstrated compelling preclinical anti-tumor activity both as a monotherapy and in combination with other cancer immunotherapies," said Dr. Pini Tsukerman, Co-Founder and Chief Scientific Officer of Nectin. Dr. Sarina Piha-Paul, Associate Professor of Investigational Cancer Therapeutics at MD Anderson is the trial Principal Investigator.NTX1088 is a first-in-class monoclonal antibody directed against a key immune checkpoint, PVR, also known as CD155. NTX1088 demonstrated superior antitumor activity compared to approved and investigational immune checkpoint inhibitors in preclinical models and had a favorable safety profile in non-human primates.is a biotechnology company aiming to transform the lives of cancer patients by leveraging its unique insights into the nectin pathway to develop the next generation of immuno-oncology (IO) therapies.